Astellas' VEOZATM (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.
Astellas' VEOZAtm (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
First-in-class treatment option reduces number and intensity of hot flashes and night sweatsÂ
TOKYO, Dec. 10, 2023 /PRNewswire/ Astellas Pharma Inc. today announced the European Commission on.
A treatment option to reduce the number and intensity of hot flashes and night sweats associated with menopause has been approved by the European Commission (EC).